Hemophilia A – Landscape & Forecast – Disease Landscape & Forecast
The hemophilia A treatment landscape has evolved with the acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment. Offering improved treatment outcomes, Hemlibra has been transformative for many inhibitor patients who were on bypass agent prophylaxis. Also, with its reduced dosing frequency and subcutaneous administration, it is a more-convenient prophylaxis option for noninhibitor patients. The next five to ten years will be exciting for the hemophilia A (with and without inhibitors) therapy market owing to the entry of an extended half-life factor VIII product (Sanofi’s BIVV001), several nonfactor agents (Sanofi’s fitusiran, Pfizer’s marstacimab, and Novo Nordisk’s concizumab and mim8), and gene therapies (BioMarin’s Roctavian, Pfizer / Sangamo Therapeutics’ giroctocogene fitelparvovec). Supported by insights from thought leaders, we assess the impact of new drug therapies on the treatment of hemophilia A.
QUESTIONS ANSWERED
- What is the current treatment landscape for hemophilia A? What are physicians’ experience and satisfaction levels with current key therapies?
- How has Hemlibra changed the treatment landscape for hemophilia A for patients with and without inhibitors?
- What clinical roles will BIVV001, concizumab, fitusiran, marstacimab, mim8, and gene therapy play in the evolving hemophilia A treatment landscape?
- How will the management of patients with or without inhibitors change when new treatment options become available?
- How will the factor VIII concentrate market evolve?
- How will nonfactor treatment options impact the multitude of brands competing for patient share?
- What impact will gene therapies have on the management of hemophilia A patients?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 19 country-specific interviews with thought-leading hematologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Diagnosed prevalence of hemophilia A +/- inhibitors by country, population segmentation by disease severity and inhibitor titer.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key hemophilia A therapies through 2032, segmented by brand and epidemiological subpopulation.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Hemophilia A - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Key Findings
- Market Outlook
- Forecast
- Market Forecast Downloads
- Market Forecast Assumption - Hemophilia A Non-Inhibitor Prophylaxis (2022-2032) - November 2023
- Market Forecast Assumption - Hemophilia A Non-Inhibitor On demand (2022-2032) - November 2023
- Market Forecast Assumption - Hemophilia A Low titer Prophylaxis (2022-2032) - November 2023
- Market Forecast Assumption - Hemophilia A Low titer On demand (2022-2032) - November 2023
- Market Forecast Assumption - Hemophilia A High titer Prophylaxis and ITI (2022-2032) - November 2023
- Market Forecast Assumption - Hemophilia A High titer On demand (2022-2032) - November 2023
- Market Forecast Dashboard - Hemophilia A Non-Inhibitor Prophylaxis (2022-2032) - November 2023
- Market Forecast Dashboard - Hemophilia A Non-Inhibitor On demand (2022-2032) - November 2023
- Market Forecast Dashboard - Hemophilia A Low titer Prophylaxis (2022-2032) - November 2023
- Market Forecast Dashboard - Hemophilia A Low titer On demand (2022-2032) - November 2023
- Market Forecast Dashboard - Hemophilia A High titer Prophylaxis and ITI (2022-2032) - November 2023
- Market Forecast Dashboard - Hemophilia A High titer On demand (2022-2032) - November 2023
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Archita Kukreja, M.B.A., M.S., Lead Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic Disorders. Archita has authored reports on hematological indications like beta thalassemia and sickle cell disease, infectious diseases, and several niche and rare indications. Prior to joining Clarivate, she was a Manager at Sanofi. She has worked on diverse custom and syndicated research project types in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, demand forecasting, commercial opportunity assessments, and market intelligence. She holds double master’s degrees in business administration (M.B.A) and in science (M.S.) with specialization in Biotechnology from Amity University, Noida, India, and Jamia Millia Islamia University, Delhi, India, respectively.
